Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 2/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | USP2 | O75604 | 3/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.38 |
| ▸ | VNN1 | O95497 | 1/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.37 |
| ▸ | TSHR | P16473 | 2/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18711632 | 0.93 | CYP3A4 (0.39) | CYP1A2TDP1USP2CYP2C19SMN1; SMN2 | |
| SCHEMBL18069128 | 0.88 | SMN1; SMN2 (0.42) | CYP1A2TDP1USP2CYP2C19SMN1; SMN2 | |
| SCHEMBL27896663 | 0.83 | RORC (0.41) | TDP1SMN1; SMN2HPGDKDM4EMEN1 | |
| SCHEMBL3869090 | 0.81 | VNN1 (0.38) | TDP1SMN1; SMN2HPGDKDM4EALDH1A1 | |
| SCHEMBL23077821 | 0.81 | CYP1A2 (0.43) | CYP1A2TDP1USP2CYP2C19SMN1; SMN2 | |
| SCHEMBL14970391 | 0.80 | SMN1; SMN2 (0.50) | CYP1A2TDP1USP2CYP2C19SMN1; SMN2 | |
| SCHEMBL18702091 | 0.80 | CYP3A4 (0.40) | MEN1KMT2AALDH1A1EPHX2PDK2 | |
| SCHEMBL15450784 | 0.79 | SMN1; SMN2 (0.45) | CYP1A2TDP1USP2CYP2C19SMN1; SMN2 | |
| SCHEMBL16876660 | 0.79 | VNN1 (0.37) | TDP1SMN1; SMN2HPGDKDM4EALDH1A1 | |
| SCHEMBL20348530 | 0.79 | PDK2 (0.41) | MEN1KMT2AALDH1A1EPHX2PDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3356345-B1 | HETEROARYL DERIVATIVES AS SEPIAPTERIN REDUCTASE INHIBITORS | MAX PLANCK GESELLSCHAFT (DE) | 2023-11-08 | — | — | EP | disclosed |
| US-20180186755-A1 | LYSYL OXIDASE-LIKE 2 INHIBITORS AND USES THEREOF | PHARMAKEA INC (US) | 2018-07-05 | — | — | US | disclosed |
| US-9637455-B2 | Heterocyclic sulfone RORγ modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-05-02 | — | — | US | disclosed |
| US-20170096435-A1 | SEPIAPTERIN REDUCTASE INHIBITORS | MAX-PLANCK-GESELLSCHAFT ZUR FOERDERUNG DER WISSENSCHAFTEN E.V. (DE) | 2017-04-06 | — | — | US | disclosed |
| US-20160326108-A1 | PYRROLIDINYL SULFONE DERIVATIVES AND THEIR USE AS ROR GAMMA MODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2016-11-10 | — | — | US | disclosed |
| US-20160326115-A1 | HETEROCYCLIC SULFONE ROR GAMMA MODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2016-11-10 | — | — | US | disclosed |
| US-9458171-B2 | Pyrrolidinyl sulfone RORγ modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-10-04 | — | — | US | disclosed |
| WO-2015103510-A1 | HETEROCYCLIC SULFONE AS ROR-GAMMA MODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-07-09 | — | — | WO | disclosed |
| US-20150191483-A1 | PYRROLIDINYL SULFONE RORGAMMA MODULATORS | BRISTOL-MYERS SQUIBB COMPANY | 2015-07-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180186755-A1 | LYSYL OXIDASE-LIKE 2 INHIBITORS AND USES THEREOF | LOXL2, LOXL1, LOX | CYP1A2 387/4885TDP1 953/4885USP2 330/4885 |
| US-20170096435-A1 | SEPIAPTERIN REDUCTASE INHIBITORS | SPR, QDPR, SRR | CYP1A2 456/4885TDP1 1662/4885USP2 3169/4885 |
| US-20160326115-A1 | HETEROCYCLIC SULFONE ROR GAMMA MODULATORS | RORC, RORB, RORA | CYP1A2 165/4885TDP1 3165/4885USP2 3080/4885 |
| US-20160326108-A1 | PYRROLIDINYL SULFONE DERIVATIVES AND THEIR USE AS ROR GAMMA MODULATORS | RORC, RORB, RORA | CYP1A2 398/4885TDP1 2490/4885USP2 3493/4885 |
| US-20150191483-A1 | PYRROLIDINYL SULFONE RORGAMMA MODULATORS | RORC, RORB, RORA | CYP1A2 430/4885TDP1 2482/4885USP2 3646/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.